InvestmentUpdated on 21 January 2026
Seed Investment in arterioscope
About
arterioscope FlexCo is a spin-off from Graz University of Technology developing an AI-powered digital biomarker platform for cardiovascular applications.
We are currently raising our first seed round to accelerate company growth and to bring our first digital biomarker module to market. Our technology enables the extraction of clinically relevant cardiovascular biomarkers from physiological signals, creating scalable digital endpoints for research and clinical use.
The company is presently financed mainly through public funding. We are now seeking our first private investment to leverage existing grants, finalize MDR certification, expand the team, and prepare the market entry in order to generate first commercial revenues.
If you are interested in an investment opportunity or a strategic exchange, please contact us directly or email hello@arterioscope.com.
Stage
- Seed and Development
Applies to
- Biology/Biotechnology
- Pharmaceuticals
- E-Health
- Diagnostics
Organisation
Similar opportunities
Product
AI-powered digital biomarker platform for clinical trial support.
- E-Health
- Pharmaceuticals
- Clinical Partner
- Biology/Biotechnology
Hermann Moser
Co-Founder & CEO at arterioscope FlexCo
Graz, Austria
Project cooperation
Evangelia Athanasiou
Business Development at 3ahealth
Nicosia, Cyprus
Service
- E-Health
- Consulting / Coaching
- Hospital/ Rehabilitation Centers
Alexandro Lahmann
CEO & Founder at LIT Health FlexCo
Berlin, Germany